Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

Eli Lilly and Company (NYSE:LLY) had its price target upped by BMO Capital Markets from $930.00 to $1,100.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ target price would suggest a potential upside of 18.60% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the company. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $950.00.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $927.48 on Thursday. The stock has a market cap of $876.82 billion, a price-to-earnings ratio of 60.62, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a 50 day moving average price of $792.03 and a 200-day moving average price of $773.89. Eli Lilly and Company has a one year low of $623.78 and a one year high of $955.46.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. increased its position in Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. increased its position in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares in the last quarter. Wellington Management Group LLP increased its position in Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after buying an additional 81,587 shares in the last quarter. Laurel Wealth Advisors LLC increased its position in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares in the last quarter. Finally, Norges Bank acquired a new position in Eli Lilly and Company during the 2nd quarter valued at about $8,827,714,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.